Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Activity
Last 14 days
Multi-Center Clinical Evaluation of the ATTUNE® Revision System in Revision Total Knee Arthroplasty
Randomized, Prospective, Multi-Center Study of the INHANCE Stemless Total Reverse Shoulder System
Multi-Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty
Multi-Center Clinical Evaluation of the ATTUNE Revision System in Complex Primary Total Knee Arthroplasty
Planned vs. Actual Acetabular Cup Position in Total Hip Arthroplasty With Non-Invasive Navigation
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Flagyl — METRONIDAZOLE IN PLASTIC CONTAINER
Application NDA018890 (NDA)
Flagyl — METRONIDAZOLE
Application NDA018889 (NDA)
Flagyl — METRO I.V. IN PLASTIC CONTAINER
Application NDA018900 (NDA)
Flagyl — METRONIDAZOLE
Application NDA018930 (NDA)
Flagyl — METRONIDAZOLE
Application NDA018845 (NDA)
Flagyl — PROTOSTAT
Application NDA018871 (NDA)
Flagyl — METRONIDAZOLE
Application NDA018818 (NDA)
Flagyl — METRONIDAZOLE
Application NDA019029 (NDA)
Flagyl — METRONIDAZOLE
Application NDA018907 (NDA)
Flagyl — METROGEL
Application NDA019737 (NDA)
Flagyl — METROGEL-VAGINAL
Application NDA020208 (NDA)
Flagyl — METROCREAM
Application NDA020531 (NDA)
Flagyl — FLAGYL
Application NDA020334 (NDA)
Flagyl — FLAGYL ER
Application NDA020868 (NDA)
Flagyl — NORITATE
Application NDA020743 (NDA)
Flagyl — METROLOTION
Application NDA020901 (NDA)
Flagyl — METROGEL
Application NDA021789 (NDA)
Flagyl — VANDAZOLE
Application NDA021806 (NDA)
Flagyl — NUVESSA
Application NDA205223 (NDA)
Flagyl — LIKMEZ
Application NDA216755 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)